⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

POLYMED - Investment Analysis: Buy Signal or Bull Trap?

← Back to List

⭐ Rating: 2.3

Last Updated Time : 19 Sept 26, 01:47 am

Key Parameters

⭐ Investment Rating: 2.3

ROE9.62 %
ROCE13.4 %
PEG Ratio2.94
Dividend Yield0.20 %
Debt to equity0.08
PAT Qtr88.1 Cr.
PAT Prev Qtr80.6 Cr.
Qtr Profit Var0.22 %
Show all parameters (20 more)
Stock CodePOLYMED
Market Cap17,591 Cr.
Current Price1,735 ₹
High / Low2,094 ₹
Stock P/E51.6
Book Value301 ₹
Face Value5.00 ₹
DMA 501,707 ₹
DMA 2001,677 ₹
Chg in FII Hold-0.36 %
Chg in DII Hold0.48 %
RSI49.6
MACD-2.83
Volume1,55,636
Avg Vol 1Wk1,05,743
Low price1,182 ₹
High price2,094 ₹
52w Index60.6 %
EPS33.2 ₹
Industry PE33.1

🏭 Industry

The pharmaceutical and medical devices industry is characterized by moderate growth driven largely by increasing healthcare spending and an aging population. Competitive pressures are intense, with established players often benefiting from brand recognition and strong distribution networks, although innovation remains crucial for sustained success.

✅ Positive

Poly Medicure demonstrates consistent profitability growth over the past two quarters, increasing PAT from 80.6 Cr to 88.1 Cr. The company’s debt-to-equity ratio of 0.08 indicates a conservative capital structure with minimal financial risk, enhancing its long-term stability and capacity for reinvestment.

⚠️ Limitation

Despite the positive profit trend, the high Stock P/E of 51.6 relative to the industry average of 33.1 suggests the stock is currently trading at a premium valuation. Furthermore, while the dividend yield of 0.20% is reasonable, it's unlikely to generate substantial income within a long-term holding strategy, and the PEG ratio of 2.94 further indicates that earnings growth may not justify the current price level.

📉 Company Negative News

Recent news highlights a decline in net profit (5.3%) alongside projected revenue increases for FY26, indicating potential headwinds despite overall topline expansion. The shareholding pattern update shows a slight reduction in FII holding, which can sometimes signal reduced institutional confidence.

🧾 Long-Term Outlook

An ideal entry price zone would be between 1,600 ₹ and 1,700 ₹, capitalizing on the current premium valuation while acknowledging the potential for future corrections. A holding period of 5-7 years is recommended, focusing on compounding returns generated by sustainable profit growth and disciplined reinvestment. Given the moderate industry growth and reasonable debt levels, a final verdict is cautiously optimistic – this stock represents a potentially durable investment if management can successfully navigate competitive pressures and maintain its profitability trajectory.

Choose Technical Analysis or Fundamental Analysis above to load it.

How POLYMED Rates Across All Strategies

★ 2.2
Enter at 1,707 ₹ – this represents a slight dip from the immediate hi…
★ 2.3
Buy at 1,725 ₹ with a stop-loss order at 1,690 ₹ – this leverages the…
Investment
★ 2.3
You're viewing this analysis below.
★ 2.7
Entry Zone: 1,700 - 1,725 ₹ (based on support levels near the 50 DMA).
★ 2.8
Given the current valuation, an entry point at 1,600 ₹ would represen…

NIFTY 50 · Investment

NEXT 50 · Investment

MIDCAP · Investment

SMALLCAP · Investment